iOmx Therapeutics develops targeted cancer immunotherapy treatments using its proprietary iOTargTM target screening platform, which leverages insights from tumor and myeloid biology. The company focuses on creating biomarker-enabled drug programs that address immune evasion in prevalent solid tumors, aiming to establish new backbone therapies with single agent activity.
Funding
$121.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many solid tumors evade immune detection and destruction through various mechanisms, limiting the effectiveness of current immunotherapies. Identifying and targeting these immune evasion mechanisms is crucial for developing more effective cancer treatments.
Solution
iOmx Therapeutics is developing targeted cancer immunotherapy treatments by leveraging its iOTargTM target screening platform, which provides insights into tumor and myeloid biology. The company focuses on creating biomarker-enabled drug programs that address immune evasion in prevalent solid tumors. iOmx aims to establish new backbone therapies with single-agent activity, offering a modality-open approach to drug development. By translating unexplored immune evasion biology into a growing pipeline, iOmx is committed to shaping the future of cancer therapy.
Target Audience
The primary target audience includes patients with prevalent solid tumors who are not responding to existing immunotherapies, as well as oncologists and researchers seeking new treatment options.
Features
- iOTargTM target screening platform for identifying novel immune evasion targets
- Focus on biomarker-enabled drug programs for personalized treatment
- Development of single-agent therapies for solid tumors
- Modality-open approach to drug development, exploring various therapeutic modalities
- Pipeline of drug programs targeting prevalent solid tumor indications